Wolfe Research Lifts Gilead Price Target to $170, Citing HIV Franchise Momentum
Wolfe Research increased its price objective on Gilead Sciences to $170 from $155 and retained an Outperform rating, pointing to continued strength in the company’s HIV portfolio. The move follows robust product growth, an above-consensus quarterly report, and a string of price-target revisions from other brokerages.